Sanofi SA (SNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 2.18 is considered Undervalued compared with the five-year average of 10.07. The fair price of Sanofi SA (SNY) is between +Inf to +Inf according to relative valuation method. Compared to the current price of 46.16 USD , Sanofi SA By Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：46.16

Fair

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Sanofi SA (SNY) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Sanofi SA (SNY) has a current Price-to-Book (P/B) ratio of 1.39. Compared to its 3-year average P/B ratio of 1.07, the current P/B ratio is approximately 30.00% higher. Relative to its 5-year average P/B ratio of 0.97, the current P/B ratio is about 43.59% higher. Sanofi SA (SNY) has a Forward Free Cash Flow (FCF) yield of approximately 9.37%. Compared to its 3-year average FCF yield of 3.99%, the current FCF yield is approximately 134.75% lower. Relative to its 5-year average FCF yield of 3.83%, the current FCF yield is about 144.67% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for SNY competitors is 4.46, providing a benchmark for relative valuation. Sanofi SA Corp (SNY.O) exhibits a P/S ratio of 2.18, which is -51.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of SNY increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of SNY in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is SNY currently overvalued or undervalued?

What is Sanofi SA (SNY) fair value?

SNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Sanofi SA (SNY) is between +Inf to +Inf according to relative valuation method.

How does SNY's valuation metrics compare to the industry average?

The average P/S ratio for SNY's competitors is 4.46, providing a benchmark for relative valuation. Sanofi SA Corp (SNY) exhibits a P/S ratio of 2.18, which is -51.18% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Sanofi SA (SNY) as of Mar 03 2026?

As of Mar 03 2026, Sanofi SA (SNY) has a P/B ratio of 1.39. This indicates that the market values SNY at 1.39 times its book value.

What is the current FCF Yield for Sanofi SA (SNY) as of Mar 03 2026?

As of Mar 03 2026, Sanofi SA (SNY) has a FCF Yield of 9.37%. This means that for every dollar of Sanofi SA's market capitalization, the company generates 9.37 cents in free cash flow.

What is the current Forward P/E ratio for Sanofi SA (SNY) as of Mar 03 2026?

As of Mar 03 2026, Sanofi SA (SNY) has a Forward P/E ratio of 0.00. This means the market is willing to pay $0.00 for every dollar of Sanofi SA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Sanofi SA (SNY) as of Mar 03 2026?

As of Mar 03 2026, Sanofi SA (SNY) has a Forward P/S ratio of 2.18. This means the market is valuing SNY at $2.18 for every dollar of expected revenue over the next 12 months.

SNY Valuation